| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Departments of Internal Medicine (D.E.S., R.S.B., D.A.A.), Pathology (T.J.G.), and Psychiatry (M.N.S.), University of Michigan Medical School, Ann Arbor, Michigan 48109; and Department of Medicine (M.D.B., R.M.S.), Division of Pulmonary and Critical Medicine, UCLA School of Medicine, Los Angeles, California 90024
Address all correspondence and requests for reprints to: David E. Schteingart. M.D., University of Michigan Medical Center, 5570 MSRB II, Box 0678, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0001. E-mail: dschtein{at}umich.edu
Abstract
A patient with adrenocortical carcinoma presented with fever,
leukocytosis, and increased acute phase reactants. The tumor was
infiltrated with neutrophils. Immunohistochemical staining of the tumor
showed positive signal for epithelial neutrophil-activating protein-78,
an angiogenic and chemotactic CXC chemokine. Conditioned medium from
tumor-derived cells (RL-251) showed high concentration of IL-8,
epithelial neutrophil-activating protein-78, Gro
, and Gro
,
angiogenic CXC chemokines with a potential role in tumorigenesis. An
adrenal cancer/severe combined immunodeficiency mouse chimera was
developed. Mice grew tumors rapidly, and circulating levels of IL-8
and epithelial neutrophil-activating protein-78 were detected. In
contrast, animals transplanted with NCI-H295 cells, a
nonchemokine-secreting cell line, grew tumors more slowly and did not
have detectable chemokine levels. Similar to the patient, mice with
RL-251 tumors developed marked leukocytosis and neutrophilia, and their
tumors were infiltrated with neutrophils. Mice were passively immunized
with epithelial neutrophil-activating protein-78 antisera. A marked
decrease in tumor growth was observed. Potential for chemokine
production by other adrenocortical tumors was investigated by RT-PCR in
archival material. Six of seven adrenal carcinomas and one of three
adenomas had cDNA for IL-8; six of seven carcinomas and the three
adenomas had cDNA for epithelial neutrophil-activating protein-78. We
concluded that the clinical presentation of this case resulted from
increased tumor production of chemotactic chemokines. Through their
angiogenic and chemotactic properties these chemokines may play an
important role in adrenal tumorigenesis.
This article has been cited by other articles:
![]() |
T. Else, T. J. Giordano, and G. D. Hammer Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wen, S. F. Giardina, D. Hamming, J. Greenman, E. Zachariah, M. D. Bacolod, H. Liu, J. Shia, P. S. Amenta, F. Barany, et al. GRO{alpha} Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1. Clin. Cancer Res., October 15, 2006; 12(20): 5951 - 5959. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Romero, G. R. Vergara, Z. Zhu, G. S. Covington, M. W. Plonczynski, L. L. Yanes, E. P. Gomez-Sanchez, and C. E. Gomez-Sanchez Interleukin-8 Synthesis, Regulation, and Steroidogenic Role in H295R Human Adrenocortical Cells Endocrinology, February 1, 2006; 147(2): 891 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rotondi, A. Falorni, A. De Bellis, S. Laureti, P. Ferruzzi, P. Romagnani, A. Buonamano, E. Lazzeri, C. Crescioli, M. Mannelli, et al. Elevated Serum Interferon-{gamma}-Inducible Chemokine-10/CXC Chemokine Ligand-10 in Autoimmune Primary Adrenal Insufficiency and in Vitro Expression in Human Adrenal Cells Primary Cultures after Stimulation with Proinflammatory Cytokines J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2357 - 2363. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Bornstein and P. J. Hornsby What Can We Learn from Gene Expression Profiling for Adrenal Tumor Management? J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1900 - 1902. [Full Text] [PDF] |
||||
![]() |
L. S. KIRSCHNER Signaling Pathways in Adrenocortical Cancer Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 222 - 239. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |